Switch to:
Also traded in: Germany, Japan

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.78
OTCPK:TKPYY's Cash to Debt is ranked lower than
61% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.55 vs. OTCPK:TKPYY: 0.78 )
Ranked among companies with meaningful Cash to Debt only.
OTCPK:TKPYY' s Cash to Debt Range Over the Past 10 Years
Min: 0.7  Med: 19.69 Max: N/A
Current: 0.78
Equity to Asset 0.48
OTCPK:TKPYY's Equity to Asset is ranked lower than
72% of the 719 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. OTCPK:TKPYY: 0.48 )
Ranked among companies with meaningful Equity to Asset only.
OTCPK:TKPYY' s Equity to Asset Range Over the Past 10 Years
Min: 0.47  Med: 0.55 Max: 0.76
Current: 0.48
0.47
0.76
Interest Coverage 8.80
OTCPK:TKPYY's Interest Coverage is ranked lower than
75% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 101.94 vs. OTCPK:TKPYY: 8.80 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:TKPYY' s Interest Coverage Range Over the Past 10 Years
Min: 3.18  Med: 189.06 Max: 1856.28
Current: 8.8
3.18
1856.28
F-Score: 6
Z-Score: 2.54
M-Score: -2.53
WACC vs ROIC
4.54%
8.09%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 10.40
OTCPK:TKPYY's Operating margin (%) is ranked higher than
57% of the 732 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.61 vs. OTCPK:TKPYY: 10.40 )
Ranked among companies with meaningful Operating margin (%) only.
OTCPK:TKPYY' s Operating margin (%) Range Over the Past 10 Years
Min: -7.27  Med: 18.74 Max: 35.13
Current: 10.4
-7.27
35.13
Net-margin (%) 8.56
OTCPK:TKPYY's Net-margin (%) is ranked higher than
59% of the 733 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.95 vs. OTCPK:TKPYY: 8.56 )
Ranked among companies with meaningful Net-margin (%) only.
OTCPK:TKPYY' s Net-margin (%) Range Over the Past 10 Years
Min: -8.2  Med: 12.39 Max: 25.85
Current: 8.56
-8.2
25.85
ROE (%) 7.66
OTCPK:TKPYY's ROE (%) is ranked higher than
55% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. OTCPK:TKPYY: 7.66 )
Ranked among companies with meaningful ROE (%) only.
OTCPK:TKPYY' s ROE (%) Range Over the Past 10 Years
Min: -6.33  Med: 8.85 Max: 15.12
Current: 7.66
-6.33
15.12
ROA (%) 3.78
OTCPK:TKPYY's ROA (%) is ranked higher than
51% of the 787 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. OTCPK:TKPYY: 3.78 )
Ranked among companies with meaningful ROA (%) only.
OTCPK:TKPYY' s ROA (%) Range Over the Past 10 Years
Min: -3.29  Med: 6.12 Max: 12
Current: 3.78
-3.29
12
ROC (Joel Greenblatt) (%) 31.15
OTCPK:TKPYY's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 777 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.38 vs. OTCPK:TKPYY: 31.15 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OTCPK:TKPYY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -19.36  Med: 48.9 Max: 207.72
Current: 31.15
-19.36
207.72
Revenue Growth (3Y)(%) 5.20
OTCPK:TKPYY's Revenue Growth (3Y)(%) is ranked lower than
51% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. OTCPK:TKPYY: 5.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OTCPK:TKPYY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0.2  Med: 5.05 Max: 11.6
Current: 5.2
0.2
11.6
EBITDA Growth (3Y)(%) -4.40
OTCPK:TKPYY's EBITDA Growth (3Y)(%) is ranked lower than
73% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. OTCPK:TKPYY: -4.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OTCPK:TKPYY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -28.3  Med: -1.15 Max: 24.8
Current: -4.4
-28.3
24.8
EPS Growth (3Y)(%) -18.50
OTCPK:TKPYY's EPS Growth (3Y)(%) is ranked lower than
80% of the 530 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. OTCPK:TKPYY: -18.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OTCPK:TKPYY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -24.5  Med: -0.8 Max: 31.4
Current: -18.5
-24.5
31.4
GuruFocus has detected 4 Warning Signs with Takeda Pharmaceutical Co Ltd $OTCPK:TKPYY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:TKPYY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with TKPYY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NYSE:TEVA, NYSE:ZTS, NAS:MYL, OTCPK:ESALY, OTCPK:SGIOY, OTCPK:MKGAY, OTCPK:MTZPY, NYSE:PRGO, OTCPK:APNHY, OTCPK:HLUYY, OTCPK:SFOSF, NYSE:RDY, OTCPK:IPSEY, OTCPK:HKMPF, OTCPK:HYPMY, NYSE:VRX, NYSE:MNK, NAS:OPK, NYSE:TARO, NYSE:PTHN » details
Traded in other countries:TKD.Germany, 4502.Japan,
Takeda Pharmaceutical Co Ltd is engaged in the manufacturing, marketing and import and export of pharmaceutical drugs.

Takeda Pharmaceutical Co Ltd was founded on June 12, 1781 and was incorporated on January 29, 1925. The Company is primarily engaged in the any manufacture and sale of pharmaceuticals, food supplements, and chemical products such as polyurethane. The Company also produces food, agrochemicals, and environment-related products such as pollution detectors. It is also engaged in the research, development, and promotion of its products through its related companies in the US, Europe, and Asia.

Ratios

vs
industry
vs
history
P/E(ttm) 24.69
TKPYY's P/E(ttm) is ranked higher than
58% of the 532 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.54 vs. TKPYY: 24.69 )
Ranked among companies with meaningful P/E(ttm) only.
TKPYY' s P/E(ttm) Range Over the Past 10 Years
Min: 6.52  Med: 20.98 Max: 90.66
Current: 24.69
6.52
90.66
Forward P/E 22.08
TKPYY's Forward P/E is ranked lower than
67% of the 67 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.16 vs. TKPYY: 22.08 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 24.69
TKPYY's PE(NRI) is ranked higher than
58% of the 533 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.54 vs. TKPYY: 24.69 )
Ranked among companies with meaningful PE(NRI) only.
TKPYY' s PE(NRI) Range Over the Past 10 Years
Min: 6.52  Med: 20.98 Max: 90.66
Current: 24.69
6.52
90.66
Price/Owner Earnings (ttm) 18.17
TKPYY's Price/Owner Earnings (ttm) is ranked higher than
72% of the 289 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.32 vs. TKPYY: 18.17 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
TKPYY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 11.64  Med: 30.58 Max: 581.37
Current: 18.17
11.64
581.37
P/B 2.03
TKPYY's P/B is ranked higher than
64% of the 751 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. TKPYY: 2.03 )
Ranked among companies with meaningful P/B only.
TKPYY' s P/B Range Over the Past 10 Years
Min: 1.22  Med: 1.55 Max: 2.44
Current: 2.03
1.22
2.44
P/S 2.11
TKPYY's P/S is ranked higher than
60% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. TKPYY: 2.11 )
Ranked among companies with meaningful P/S only.
TKPYY' s P/S Range Over the Past 10 Years
Min: 1.67  Med: 2.19 Max: 12.29
Current: 2.11
1.67
12.29
PFCF 101.69
TKPYY's PFCF is ranked lower than
87% of the 202 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.11 vs. TKPYY: 101.69 )
Ranked among companies with meaningful PFCF only.
TKPYY' s PFCF Range Over the Past 10 Years
Min: 10.03  Med: 85.7 Max: 1630.33
Current: 101.69
10.03
1630.33
POCF 33.08
TKPYY's POCF is ranked lower than
75% of the 269 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. TKPYY: 33.08 )
Ranked among companies with meaningful POCF only.
TKPYY' s POCF Range Over the Past 10 Years
Min: 7.75  Med: 33.56 Max: 69.14
Current: 33.08
7.75
69.14
EV-to-EBIT 20.42
TKPYY's EV-to-EBIT is ranked higher than
50% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.32 vs. TKPYY: 20.42 )
Ranked among companies with meaningful EV-to-EBIT only.
TKPYY' s EV-to-EBIT Range Over the Past 10 Years
Min: -47.1  Med: 11.2 Max: 46.2
Current: 20.42
-47.1
46.2
EV-to-EBITDA 11.47
TKPYY's EV-to-EBITDA is ranked higher than
71% of the 562 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.15 vs. TKPYY: 11.47 )
Ranked among companies with meaningful EV-to-EBITDA only.
TKPYY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -321.6  Med: 10.7 Max: 237.7
Current: 11.47
-321.6
237.7
Shiller P/E 10.31
TKPYY's Shiller P/E is ranked higher than
94% of the 158 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.98 vs. TKPYY: 10.31 )
Ranked among companies with meaningful Shiller P/E only.
TKPYY' s Shiller P/E Range Over the Past 10 Years
Min: 8.7  Med: 10.21 Max: 10.86
Current: 10.31
8.7
10.86
Current Ratio 1.84
TKPYY's Current Ratio is ranked lower than
60% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.34 vs. TKPYY: 1.84 )
Ranked among companies with meaningful Current Ratio only.
TKPYY' s Current Ratio Range Over the Past 10 Years
Min: 1.21  Med: 2.1 Max: 4
Current: 1.84
1.21
4
Quick Ratio 1.54
TKPYY's Quick Ratio is ranked lower than
57% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. TKPYY: 1.54 )
Ranked among companies with meaningful Quick Ratio only.
TKPYY' s Quick Ratio Range Over the Past 10 Years
Min: 1  Med: 1.74 Max: 3.64
Current: 1.54
1
3.64
Days Inventory 168.12
TKPYY's Days Inventory is ranked lower than
73% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.25 vs. TKPYY: 168.12 )
Ranked among companies with meaningful Days Inventory only.
TKPYY' s Days Inventory Range Over the Past 10 Years
Min: 132.84  Med: 162.63 Max: 180.99
Current: 168.12
132.84
180.99

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.01
TKPYY's Dividend Yield is ranked higher than
89% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.64 vs. TKPYY: 4.01 )
Ranked among companies with meaningful Dividend Yield only.
TKPYY' s Dividend Yield Range Over the Past 10 Years
Min: 2.71  Med: 4.43 Max: 6.48
Current: 4.01
2.71
6.48
Dividend Payout 0.93
TKPYY's Dividend Payout is ranked lower than
88% of the 389 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.33 vs. TKPYY: 0.93 )
Ranked among companies with meaningful Dividend Payout only.
TKPYY' s Dividend Payout Range Over the Past 10 Years
Min: 0.33  Med: 0.62 Max: 1.77
Current: 0.93
0.33
1.77
Forward Dividend Yield 3.80
TKPYY's Forward Dividend Yield is ranked higher than
89% of the 605 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.79 vs. TKPYY: 3.80 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.01
TKPYY's Yield on cost (5-Year) is ranked higher than
76% of the 773 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.19 vs. TKPYY: 4.01 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TKPYY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.71  Med: 4.43 Max: 6.48
Current: 4.01
2.71
6.48
3-Year Average Share Buyback Ratio 0.30
TKPYY's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 429 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. TKPYY: 0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TKPYY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.3  Med: 0 Max: 3.9
Current: 0.3
-0.3
3.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 7.20
TKPYY's Price/Tangible Book is ranked lower than
76% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.47 vs. TKPYY: 7.20 )
Ranked among companies with meaningful Price/Tangible Book only.
TKPYY' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.85  Med: 6.99 Max: 13.07
Current: 7.2
1.85
13.07
Price/Projected FCF 2.10
TKPYY's Price/Projected FCF is ranked higher than
57% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.72 vs. TKPYY: 2.10 )
Ranked among companies with meaningful Price/Projected FCF only.
TKPYY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.14  Med: 1.42 Max: 2.21
Current: 2.1
1.14
2.21
Price/Median PS Value 0.97
TKPYY's Price/Median PS Value is ranked higher than
65% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. TKPYY: 0.97 )
Ranked among companies with meaningful Price/Median PS Value only.
TKPYY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.81  Med: 1 Max: 5.2
Current: 0.97
0.81
5.2
Price/Graham Number 2.81
TKPYY's Price/Graham Number is ranked lower than
61% of the 458 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.21 vs. TKPYY: 2.81 )
Ranked among companies with meaningful Price/Graham Number only.
TKPYY' s Price/Graham Number Range Over the Past 10 Years
Min: 0.67  Med: 2.58 Max: 4.79
Current: 2.81
0.67
4.79
Earnings Yield (Greenblatt) (%) 4.90
TKPYY's Earnings Yield (Greenblatt) (%) is ranked higher than
65% of the 760 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. TKPYY: 4.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TKPYY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.2  Med: 6.9 Max: 23.8
Current: 4.9
2.2
23.8
Forward Rate of Return (Yacktman) (%) -27.08
TKPYY's Forward Rate of Return (Yacktman) (%) is ranked lower than
94% of the 343 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.72 vs. TKPYY: -27.08 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TKPYY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -46.9  Med: -16.6 Max: 15.8
Current: -27.08
-46.9
15.8

More Statistics

Revenue (TTM) (Mil) $15,903
EPS (TTM) $ 0.88
Beta0.31
Short Percentage of Float0.00%
52-Week Range $19.96 - 25.40
Shares Outstanding (Mil)1,567.30

Analyst Estimate

Mar17 Mar18
Revenue (Mil $) 14,952 15,822
EPS ($) 0.71 0.92
EPS w/o NRI ($) 0.71 0.92
EPS Growth Rate
(3Y to 5Y Estimate)
1.82%
Dividends Per Share ($) 0.78 0.78
» More Articles for OTCPK:TKPYY

Headlines

Articles On GuruFocus.com
Teva Is a Hold Nov 30 2016 
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 
5 Popular Asian Stocks Held By the Gurus Apr 16 2015 
Don't Quit on Teva Just Yet Feb 20 2014 
Soros´ Bet on Teva’s Transition (A Transition for Better or for Worse?) Dec 18 2013 
T. Rowe Price Japan Fund Top 5 New Buys Oct 17 2013 

More From Other Websites
Ariad played hardball to boost Takeda buyout price, federal filings show Jan 20 2017
Takeda Recognized as One of the Global 100 Most Sustainable Corporations for Second Consecutive Year Jan 19 2017
Takeda Commences Cash Tender Offer for All Outstanding Shares of ARIAD Pharmaceuticals, Inc. Jan 19 2017
Takeda and Ovid Therapeutics Announce Innovative Clinical Development and Commercialization... Jan 18 2017
[$$] US biotech Ovid to develop Takeda epilepsy drug in outsourcing tie-up Jan 18 2017
Biotech Stock Roundup: ARIAD to be Acquired for $5.2B, Vertex Outlook Falls Short Jan 11 2017
Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement... Jan 11 2017
Former Ariad CEO Berger says Takeda deal was 'merely a matter of time' Jan 11 2017
[$$] Japan's Takeda Looks to More Acquisitions to Fuel Global Growth Jan 10 2017
4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal Jan 10 2017
ARIAD Pharma Stock Gains on Acquisition Deal with Takeda Jan 10 2017
Takeda Takes the Hard Road Jan 10 2017
Takeda Pharmaceutical Company Limited -- Moody's reviews Takeda Pharmaceutical's ratings for... Jan 10 2017
Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal Jan 10 2017
Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal Jan 10 2017
Japan's Takeda ready for fresh acquisitions after $5.2 bln Ariad deal Jan 10 2017
Japan's Takeda to buy U.S. cancer drug maker Ariad in $5.2 billion deal Jan 09 2017
Japan's Takeda to buy U.S. cancer drug maker Ariad in $5.2 billion deal Jan 09 2017
[$$] Takeda to Buy Ariad for $4.7 Billion Jan 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)